Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review

被引:28
|
作者
Schlager, Lukas [1 ]
Loiskandl, Michaela [1 ]
Aletaha, Daniel [1 ]
Radner, Helga [1 ]
机构
[1] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
关键词
rheumatoid arthritis; bDMARD; tsDMARD; discontinuation; successful discontinuation; predictor; SUSTAINED REMISSION; CERTOLIZUMAB PEGOL; DOUBLE-BLIND; MULTICENTER; ETANERCEPT; WITHDRAWAL; THERAPY; INFLIXIMAB; ABATACEPT; RECOMMENDATIONS;
D O I
10.1093/rheumatology/kez278
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To systematically review possible predictors of successful discontinuation of biologic or targeted synthetic DMARDs (b/tsDMARDs) in RA patients in remission or low disease activity. Methods MEDLINE database and Cochrane Library were scanned for studies that discontinued b/tsDMARDs in remission/low disease activity and searched for predictors of successful discontinuation. Additionally, EULAR and ACR meeting abstracts were hand searched. Results Thirty-four studies with a total of 5724 patients were included. Predictors of successful b/tsDMARD discontinuation were (number of studies): low disease activity (n = 13), better physical function (n = 6), low or absence of rheumatoid factor (n = 5) or ACPA (n = 3), low levels of CRP (n = 3) or ESR (n = 3), shorter disease duration (n = 3), low signals of disease activity by ultrasound (n = 3). Only one study with high risk of bias was identified on tsDMARD discontinuation. Conclusion Several predictors of successful bDMARD discontinuation were identified. Although studies are heterogeneous, these predictors may inform clinical decision making in patients who are considered for a potential bDMARD discontinuation.
引用
收藏
页码:324 / 334
页数:11
相关论文
共 50 条
  • [1] Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis
    Convertino, Irma
    Lucenteforte, Ersilia
    Arzenton, Elena
    Giometto, Sabrina
    De Luca, Giulia
    Malanima, Marco
    Ferraro, Sara
    Bonaso, Marco
    Cappello, Emiliano
    Valdiserra, Giulia
    Cazzato, Massimiliano
    Moretti, Ugo
    Mosca, Marta
    Gini, Rosa
    Tuccori, Marco
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 171 - 171
  • [2] BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON A SPANISH REGISTRY: PREDICTORS OF THERAPY DISCONTINUATION DUE TO REMISSION
    Hernandez, M. V.
    Gomez-Puerta, J. A.
    Canete, J. D.
    Gomez-Reino, J. J.
    Sanmarti, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 464 - 465
  • [3] Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review
    Kuijper, T. Martijn
    Lamers-Karnebeek, Femke B. G.
    Jacobs, Johannes W. G.
    Hazes, Johanna M. W.
    Luime, Jolanda J.
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (11) : 2012 - 2022
  • [4] THE IMPACT OF AGE ON DISCONTINUATION OF BIOLOGIC DMARDs IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Rivera Teran, V.
    Sicsik, S.
    Vega-Morales, D.
    Irazoque-Palazuelos, F.
    Miranda, D.
    Casasola, J. C.
    Carrilo, S.
    Pena, A.
    Castillo Ortiz, A.
    Munoz-Monroy, O. E.
    Duran Barragan, S.
    Paz, A.
    Torres Valdez, E.
    Valdes Corona, L. F.
    Xibille Friedmann, D. X.
    Zamora, E.
    Ramos, A.
    Santana, N.
    Vazquez, M.
    Guerrero, F.
    Zepeda, C.
    Alvarado, K.
    Rivera, M.
    Alpizar-Rodriguez, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 559 - 560
  • [5] DISCONTINUATION OF BIOLOGIC DMARDS IN A REALLIFE POPULATION OF PATIENTS IN REMISSION: OUTCOME AND PREDICTORS
    Arnold, S.
    Jaeger, V. K.
    Scherer, A.
    Walker, U. A.
    Kyburz, D.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 330 - 331
  • [6] No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
    Huysen, L. Twee
    van den Ende, C. H.
    Beeren, F. M. M.
    Been, E. M. J.
    van den Hoogen, F. H. J.
    den Broeder, A. A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission
    Terslev, Lene
    Brahe, Cecilie Heegaard
    Hetland, Merete Lund
    Georgiadis, Stylianos
    Ellegaard, Karen
    Juul, Lars
    Tuan Huynh
    Dohn, Uffe Moller
    Fana, Viktoria
    Moller, Torsten
    Krabbe, Simon
    Ornbjerg, Lykke Midtboll
    Glinatsi, Daniel
    Rogind, Henrik
    Hansen, Anette
    Norregaard, Jesper
    Jacobsen, Soren
    Jensen, Dorte Vendelbo
    Manilo, Natalia
    Asmussen, Karsten
    Boesen, Mikael
    Rastiemadabadi, Zoreh
    Morsel-Carlsen, Lone
    Moller, Jakob Mollenbach
    Krogh, Niels Steen
    Ostergaard, Mikkel
    [J]. RHEUMATOLOGY, 2021, 60 (12) : 5549 - 5559
  • [8] Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
    Pang, Mengduan
    Sun, Zhe
    Zhang, Hongfeng
    [J]. MEDICINE, 2022, 101 (32)
  • [9] COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
    Tsai, Jih-Jin
    Liu, Li-Teh
    Chen, Chun-Hong
    Chen, Liang-Jen
    Wang, Shiow-Ing
    Wei, James Cheng-Chung
    [J]. RMD OPEN, 2023, 9 (03):
  • [10] Predictors for Remission in Rheumatoid Arthritis Patients: A Systematic Review
    Katchamart, Wanruchada
    Johnson, Sindhu
    Lin, Hsing-Ju Lucy
    Phumethum, Veerapong
    Salliot, Carine
    Bombardier, Claire
    [J]. ARTHRITIS CARE & RESEARCH, 2010, 62 (08) : 1128 - 1143